{
    "clinical_study": {
        "@rank": "149750", 
        "acronym": "SNO2", 
        "arm_group": [
            {
                "arm_group_label": "Active", 
                "arm_group_type": "Experimental", 
                "description": "N91115"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Non-active"
            }
        ], 
        "brief_summary": {
            "textblock": "A study in healthy subjects to assess the safety, tolerability, and pharmacokinetics (PK) of\n      N91115."
        }, 
        "brief_title": "MAD Study Evaluating the Safety, Tolerability, and PK Effects of N91115 in Healthy Subjects", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This Phase 1 study in healthy subjects is being conducted to assess the safety,\n      tolerability, and pharmacokinetics (PK) of N91115."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject voluntarily agrees to participate in this study and signs an Institutional\n             Review Board (IRB)-approved informed consent prior to performing any of the screening\n             procedures and in the opinion of the PI complies with all the requirements of the\n             study.\n\n          -  Subject is healthy, determined at the screening medical evaluation (including but not\n             limited to medical history, physical examination and clinical laboratory\n             evaluations).\n\n          -  Subject is Caucasian.\n\n          -  Female subject must be of non-childbearing potential (surgically sterile\n             [hysterectomy or bilateral tubal ligation] or post-menopausal \u2265 1 year with follicle\n             stimulating hormone [FSH] > 40 U/L).  Women receiving hormone replacement therapy\n             (HRT) are eligible to enroll.\n\n          -  Male subject must agree to use condoms and refrain from sperm donation from Day 1\n             until 30 days post last dose or have documentation of vasectomy.\n\n          -  Subject has a body weight > 50 kg and BMI between 19.5 and 32 kg/m2, inclusive, at\n             screening.\n\n          -  Subject has no clinically significant abnormal findings  related to their systolic or\n             diastolic BP, per the investigator's judgment, at screening or Day  1.\n\n          -  Subject has no clinically significant abnormal findings in 12 lead ECG, per the\n             investigator's judgment, at screening.\n\n        Exclusion Criteria:\n\n          -  Subject has clinically significant history or evidence of cardiovascular,\n             respiratory, hepatic, renal, gastrointestinal, endocrine, neurological,\n             immunological, or psychiatric disorder(s) as determined by the investigator or\n             designee.\n\n          -  Subject has clinically significant abnormalities on a 12 lead ECG done at screening\n\n          -  Subject has clinically significant abnormalities on a 48-hour ambulatory ECG done at\n             screening\n\n          -  Subject has any disorder that would interfere with the absorption, distribution,\n             metabolism, or excretion of drugs.\n\n          -  Subject has any concurrent disease or condition that, in the opinion of the\n             investigator, would make the subject unsuitable for participation in the clinical\n             study.\n\n          -  Subject is unlikely to comply with the protocol requirements, instructions, and study\n             related restrictions; e.g., uncooperative attitude, unavailable for follow-up call,\n             and/or improbability of completing the clinical study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013388", 
            "org_study_id": "N91115-1H-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Active", 
                "description": "Given PO daily for 14 days", 
                "intervention_name": "Active N91115", 
                "intervention_type": "Drug", 
                "other_name": "N91115"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Given PO daily for 14 days", 
                "intervention_name": "Non-active Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "N91115", 
            "GSNORi", 
            "SNO"
        ], 
        "lastchanged_date": "January 7, 2014", 
        "link": [
            {
                "description": "Home Page", 
                "url": "http://n30pharma.com"
            }, 
            {
                "description": "Phase 1 Unit", 
                "url": "http://davitaclinicalresearch.com"
            }
        ], 
        "location": {
            "contact": {
                "email": "marla.elhard@davita.com", 
                "last_name": "Marla Elhard, BSN RN CCRC", 
                "phone": "303-566-3005"
            }, 
            "contact_backup": {
                "email": "chris.galloway@davita.com", 
                "last_name": "Christopher Galloway, MD", 
                "phone": "(303) 566-3008"
            }, 
            "facility": {
                "address": {
                    "city": "Lakewood", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80228"
                }, 
                "name": "DaVita Clinical Research"
            }, 
            "investigator": {
                "last_name": "Christopher Galloway, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects", 
        "overall_contact": {
            "email": "janice.troha@n30pharma.com", 
            "last_name": "Janice M Troha", 
            "phone": "720-945-7714"
        }, 
        "overall_contact_backup": {
            "email": "steven.shoemaker@n30pharma.com", 
            "last_name": "Steven A Shoemaker, MD", 
            "phone": "720-560-2167"
        }, 
        "overall_official": [
            {
                "affiliation": "Davita Clinical Research", 
                "last_name": "Christopher Galloway, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "N30 Pharmaceuticals, Inc.", 
                "last_name": "Steven A Shoemaker, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of subjects with adverse events as measured by, but not limited to, ambulatory ECG monitoring, telemetry, 12-Lead ECGs, abnormal clinical labs, pulse oximetry and vital signs.", 
            "measure": "Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "21 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013388"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To assess the pharmacokinetics of N91115 after multiple doses over 14 days by measuring plasma concentrations of N91115 and its primary metabolite, N91288.", 
            "measure": "PK", 
            "safety_issue": "No", 
            "time_frame": "14 Days"
        }, 
        "source": "N30 Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "N30 Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}